Search Results 13071-13080 of 40293 for oral
Previous exposure to cenobamate or sensitivity/allergy to components of the oral suspension. Any potential exception to the inclusion as well as exclusion ...
* Has the ability to swallow and retain oral medication * Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have ...
Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas. Obstetrics & Gynecology. 2023; doi:10.1097/AOG.0000000000005145 ...
Previous exposure to carisbamate or sensitivity/allergy to components of the oral suspension. Note: Other protocol defined Inclusion/Exclusion Criteria may ...
No concurrent hormonal oral contraceptive use. Exclusion Criteria: (ANY of the following, both strata). Known to meet the criteria for primary myelofibrosis ...
Oral and Maxillofacial Surgery · Oral Cavity Cancer and Reconstruction Clinic in Minnesota · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology ...
... Oral and throat cancer, Adenocarcinoma, Tongue base cancer, Oropharyngeal cancer. Show more areas of focus for Eric J. Moore, M.D.. Research. Sarcoma research ...
... Oral and throat cancer, Adenocarcinoma, Laryngeal cancer, Carotid body tumor, Tongue base cancer, Mouth tumor, Salivary gland cancer, Parotid cancer ...
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!